Stock Analiz

Evommune, Inc. EVMN

Biotechnology: Pharmaceutical Preparations · IPO 2025 · data as of November 13, 2026

$7.63Market cap $315M
Open the interactive analysis →

Evommune, Inc. (EVMN) is a healthcare company listed in the US with a market value of about $315M. In fiscal year 2025 it had revenue of $13M and net income of -$69M, a net margin of -529.8%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -39%.

About Evommune

Evommune is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2025. It was profitable in 0 of the last 2 years in our data. It spends 570% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B1.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-28.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)85.7%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-742.1%
ROIC (5-yr avg.)-39.1%
Profitable years (of last 10)0
Years paying a dividend1

Financials, last 2 years

Fiscal year20252024
Revenue$13M$7M
Net income-$69M-$67M
Free cash flow-$77M-$58M
EPS (diluted)$-1.60$-6.47
Net margin-529.8%-954.4%
ROIC-39.1%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 9 analysts is $21.89, 187% above the current price; targets range from $8.00 to $28.00; the consensus rating is “Buy”; expected EPS is $-3.28 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Evommune pay a dividend?

Not currently.

Is Evommune a good stock to buy?

We do not give buy or sell advice. Evommune scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.